2.42

0.83% 0.02

After Hours: 2.41 -0.010 -0.41%

Prophase Labs Inc (PRPH)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Prophase Labs Inc stock is traded at $2.42, with a volume of 17,944. It is up +0.83% in the last 24 hours and down -10.04% over the past month. ProPhase Labs Inc is a diversified company that offers a range of services including diagnostic testing, genomics testing and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers and government organizations. The Consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of OTC consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services.

Previous Close:

$2.40

Open:

$2.38

24h Volume:

17,944

Relative Volume:

0.56

Market Cap:

$45.75M

Revenue:

$62.71M

Net Income/Loss:

$-10.48M

P/E Ratio:

-8.963

EPS:

-0.27

Net Cash Flow:

$-13.77M

1W Performance:

+1.68%

1M Performance:

-10.04%

6M Performance:

-62.60%

1Y Performance:

-44.62%

1-Day Range:

$2.3001

$2.42

1-Week Range:

$2.00

$2.45

52-Week Range:

$2.00

$7.48

Prophase Labs Inc Stock (PRPH) Company Profile

Name

Prophase Labs Inc

Sector

Healthcare (1190)

Industry

Diagnostics & Research (58)

Phone

(215) 345-0919

Address

711 STEWART AVE, SUITE 200, NEW YORK, PA

Employee

113

Twitter

Next Earnings Date

2024-08-14

Latest SEC Filings

PRPH's Discussions on Twitter

Prophase Labs Inc Stock (PRPH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-21	Initiated	H.C. Wainwright	Buy
Oct-13-21	Downgrade	Dawson James	Buy → Neutral
Jan-20-21	Initiated	Dawson James	Buy

Prophase Labs Inc Stock (PRPH) Latest News

Sep 26, 2024

ProPhase Labs stock hits 52-week low at $2.02 By Investing.com - Investing.com Australia

Sep 26, 2024

ProPhase Labs reports non-compliance with Nasdaq rules By Investing.com - Investing.com South Africa

Sep 26, 2024

ProPhase Labs reports non-compliance with Nasdaq rules By Investing.com - Investing.com Canada

Sep 26, 2024

ProPhase Labs reports non-compliance with Nasdaq rules - Investing.com India

Sep 26, 2024

ProPhase Labs Seeks Director Amidst Nasdaq Compliance Issue - TipRanks

Sep 26, 2024

ProPhase Labs reports non-compliance with Nasdaq rules By Investing.com - Investing.com UK

Sep 26, 2024

ProPhase Labs stock hits 52-week low at $2.02 By Investing.com - Investing.com Canada

Sep 26, 2024

Sep 24, 2024

Priority Technology (NASDAQ:PRTH) Reaches New 1-Year High After Analyst Upgrade - MarketBeat

Sep 24, 2024

Primoris Services Co. (NASDAQ:PRIM) Shares Sold by Paradigm Capital Management Inc. NY - Defense World

Sep 24, 2024

PROCEPT BioRobotics Co. (NASDAQ:PRCT) Given Consensus Rating of “Buy” by Analysts - Defense World

Sep 24, 2024

Sep 23, 2024

Views of Wall Street’s Leading Experts on Proto Labs Inc - SETE News

Sep 23, 2024

Tri Locum Partners LP Trims Position in Praxis Precision Medicines, Inc. (NASDAQ:PRAX) - MarketBeat

Sep 23, 2024

New underwriter set to launch with ex-Hiscox and AIG leader as chief executive - Insurance Times

Sep 23, 2024

Renaissance Technologies LLC Purchases 106,423 Shares of Proto Labs, Inc. (NYSE:PRLB) - Defense World

Sep 23, 2024

Sep 21, 2024

Transatlantique Private Wealth LLC Buys Shares of 150,000 PROCEPT BioRobotics Co. (NASDAQ:PRCT) - Defense World

Sep 21, 2024

Sep 19, 2024

Progyny Stock Faces Its Biggest Drop Ever After Losing a Major Client. Why These Analysts Like the Stock. - Barron's

Sep 19, 2024

Mark Sheptoff Financial Planning LLC Purchases New Holdings in PROCEPT BioRobotics Co. (NASDAQ:PRCT) - Defense World

Sep 19, 2024

Sep 18, 2024

Progyny Shares Fall 20% After Announcing It Will Lose 'Significant' Client - MarketWatch

Sep 18, 2024

Priority Technology (NASDAQ:PRTH) Hits New 52-Week High at $6.90 - Defense World

Sep 18, 2024

Data clang on Street for Prelude but SMARCA2 overtures continue - BioWorld Online

Sep 18, 2024

Prelude Therapeutics (NASDAQ:PRLD) Receives “Market Outperform” Rating from JMP Securities - Defense World

Sep 17, 2024

Sep 03, 2024

ProPhase Labs, Inc. (NASDAQ:PRPH) Q2 2024 Earnings Call Transcript - MSN

Sep 03, 2024

Aug 22, 2024

ProPhase Labs secures $10M in amended note agreement By Investing.com - Investing.com Canada

Aug 22, 2024

ProPhase Labs secures $10M in amended note agreement - Investing.com

Aug 22, 2024

Aug 19, 2024

ProPhase Labs to Present at August 20th Virtual Investor Summit Microcap Event - GlobeNewswire

Aug 19, 2024

ProPhase Labs to Present at August 20th Virtual Investor Summit Microcap Event - StockTitan

Aug 19, 2024

ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Acquired by Vanguard Group Inc. - Defense World

Aug 19, 2024

Aug 18, 2024

PRPH (ProPhase Labs) Inventory-to-Revenue : 1.54 (As of Jun. 2024) - GuruFocus.com

Aug 18, 2024

Aug 16, 2024

PRPH (ProPhase Labs) Ending Cash Position : $2.37 Mil (As of Jun. 2024) - GuruFocus.com

Aug 16, 2024

PRPH (ProPhase Labs) Machinery, Furniture, Equipment : $0.00 Mil (As of Jun. 2024) - GuruFocus.com

Aug 16, 2024

PRPH (ProPhase Labs) Quick Ratio : 1.44 (As of Jun. 2024) - GuruFocus.com

Aug 16, 2024

PRPH (ProPhase Labs) Volatility : 80.80% (As of Aug. 16, 2024) - GuruFocus.com

Aug 16, 2024

Aug 15, 2024

PRPH (ProPhase Labs) Net Income From Continuing Operations : $-26.31 Mil (TTM As of Jun. 2024) - GuruFocus.com

Aug 15, 2024

PRPH (ProPhase Labs) COGS-to-Revenue : 1.19 (As of Jun. 2024) - GuruFocus.com

Aug 15, 2024